EPS for Avadel Pharmaceuticals plc (AVDL) Expected At $-0.37

July 14, 2018 - By Eugene Smith

Analysts expect Avadel Pharmaceuticals plc (NASDAQ:AVDL) to report $-0.37 EPS on August, 14.They anticipate $0.56 EPS change or 294.74 % from last quarter’s $0.19 EPS. After having $-0.34 EPS previously, Avadel Pharmaceuticals plc’s analysts see 8.82 % EPS growth. The stock decreased 0.14% or $0.01 during the last trading session, reaching $7.11. About 159,889 shares traded. Avadel Pharmaceuticals plc (NASDAQ:AVDL) has declined 31.82% since July 14, 2017 and is downtrending. It has underperformed by 44.39% the S&P500.

Avadel Pharmaceuticals PLC identifies, develops, and commercializes pharmaceutical products for primary care and sterile injectable markets in the United States, France, and Ireland. The company has market cap of $261.26 million. The company's owns and develops drug delivery platforms, such as Micropump, a microparticulate system that allows the development of modified and/or controlled release of solid and oral dosage formulations of drugs; LiquiTime, which allows development of modified/controlled release liquid suspension formulations; Trigger Lock that allows development of abuse-deterrent modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, a hydrogel depot technology that allows the development of extended/modified release of injectable dosage formulations of drugs. It has a 9.77 P/E ratio. The Company’s lead products include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection used to treat hypotension; and Akovaz, an ephedrine sulfate injection.

Another recent and important Avadel Pharmaceuticals plc (NASDAQ:AVDL) news was published by Benzinga.com which published an article titled: “Benzinga’s Daily Biotech Pulse: Epidiolex, Roche’s Influenza Drug Gets Priority Review Status, Xeris Jumps On …” on June 26, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: